|
SAN DIEGO, June 8, 2026 /PRNewswire/ -- Sapu Bioscience LLC announced the expansion of its Phase 1b clinical development program for Sapu003 (Everolimus for Injection) and the appointment of Global Clinical Trials (GCT) as the lead contract research organization supporting international execution of Study SP-03-B101.
The announcement follows recent regulatory approvals supporting the study expansion and CRO transition and represents an important milestone in the evolution of the Sapu003 clinical program from its initial Australian clinical footprint toward a broader multinational development strategy.
GCT was selected following a competitive evaluation process that assessed international oncology expertise, regulatory capabilities, operational execution, clinical quality systems, and global logistics infrastructure. Following its appointment, GCT successfully completed key regulatory submissions ahead of schedule and has initiated clinical operations, regulatory coordination, site activation activities, investigational product logistics, and study management functions.
The appointment supports the expansion of the SP-03-B101 study beyond Australia into Europe and international territories and represents an important step in establishing the clinical, operational, and regulatory infrastructure necessary to support future multinational Phase 3 development. By building an international clinical network early in development, Sapu Nano aims to position Sapu003 for efficient advancement into global registrational studies following successful completion of ongoing clinical evaluation.
SP-03-B101 is an open-label Phase 1b dose-escalation study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of Sapu003 in patients with advanced mTOR-sensitive solid tumors.
"Sapu003 has progressed from concept through formulation development, manufacturing, regulatory approval, and clinical evaluation in a remarkably short period of time," said Dr. Vuong Trieu, Chief Executive Officer. "The expansion of the program beyond Australia and the appointment of GCT provide the international infrastructure necessary to support continued clinical development. We believe these milestones position Sapu003 for broader global evaluation and potentially future registrational studies while expanding access for patients with advanced cancers."
Sapu003 is a proprietary intravenous formulation of everolimus developed using Sapu Nano's Deciparticle™ platform technology. The program is designed to address limitations associated with oral everolimus administration, including variable absorption, food effects, and first-pass metabolism, while providing more predictable systemic drug exposure through intravenous delivery.
The Company expects the expanded international footprint and integrated clinical operations platform established through GCT to support continued enrollment, future site expansion, and long-term global development objectives for the Sapu003 program.
About Sapu Nano's Deciparticle™
Sapu Nano's Deciparticle™ is a proprietary nanomedicine platform designed to formulate highly water-insoluble therapeutics into ultra-small nanoparticles for intravenous administration. The platform utilizes amphiphilic polymer architectures intended to improve aqueous compatibility, stability, manufacturability, and translational flexibility across multiple therapeutic classes.
About Sapu Nano
Sapu Nano is a biotechnology company developing next-generation nanomedicine platforms to improve drug delivery, enhance therapeutic index, and unlock new clinical potential for established and novel therapeutics, with a primary focus in oncology. For more information, visit www.sapunano.com.
Media Contact
Sapu Nano
10801 Thornmint Rd., Suite 150
San Diego, CA 92127
Phone: (858) 521-8037
Email: info@sapunano.com
SAN DIEGO, June 8, 2026 /PRNewswire/ -- Sapu Bioscience LLC announced the expansion of its Phase 1b clinical development program for Sapu003 (Everolimus for Injection) and the appointment of Global Clinical Trials (GCT) as the lead contract research organization supporting international execution of Study SP-03-B101.
The announcement follows recent regulatory approvals supporting the study expansion and CRO transition and represents an important milestone in the evolution of the Sapu003 clinical program from its initial Australian clinical footprint toward a broader multinational development strategy.
GCT was selected following a competitive evaluation process that assessed international oncology expertise, regulatory capabilities, operational execution, clinical quality systems, and global logistics infrastructure. Following its appointment, GCT successfully completed key regulatory submissions ahead of schedule and has initiated clinical operations, regulatory coordination, site activation activities, investigational product logistics, and study management functions.
The appointment supports the expansion of the SP-03-B101 study beyond Australia into Europe and international territories and represents an important step in establishing the clinical, operational, and regulatory infrastructure necessary to support future multinational Phase 3 development. By building an international clinical network early in development, Sapu Nano aims to position Sapu003 for efficient advancement into global registrational studies following successful completion of ongoing clinical evaluation.
SP-03-B101 is an open-label Phase 1b dose-escalation study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of Sapu003 in patients with advanced mTOR-sensitive solid tumors.
"Sapu003 has progressed from concept through formulation development, manufacturing, regulatory approval, and clinical evaluation in a remarkably short period of time," said Dr. Vuong Trieu, Chief Executive Officer. "The expansion of the program beyond Australia and the appointment of GCT provide the international infrastructure necessary to support continued clinical development. We believe these milestones position Sapu003 for broader global evaluation and potentially future registrational studies while expanding access for patients with advanced cancers."
Sapu003 is a proprietary intravenous formulation of everolimus developed using Sapu Nano's Deciparticle™ platform technology. The program is designed to address limitations associated with oral everolimus administration, including variable absorption, food effects, and first-pass metabolism, while providing more predictable systemic drug exposure through intravenous delivery.
The Company expects the expanded international footprint and integrated clinical operations platform established through GCT to support continued enrollment, future site expansion, and long-term global development objectives for the Sapu003 program.
About Sapu Nano's Deciparticle™
Sapu Nano's Deciparticle™ is a proprietary nanomedicine platform designed to formulate highly water-insoluble therapeutics into ultra-small nanoparticles for intravenous administration. The platform utilizes amphiphilic polymer architectures intended to improve aqueous compatibility, stability, manufacturability, and translational flexibility across multiple therapeutic classes.
About Sapu Nano
Sapu Nano is a biotechnology company developing next-generation nanomedicine platforms to improve drug delivery, enhance therapeutic index, and unlock new clinical potential for established and novel therapeutics, with a primary focus in oncology. For more information, visit www.sapunano.com.
Media Contact
Sapu Nano
10801 Thornmint Rd., Suite 150
San Diego, CA 92127
Phone: (858) 521-8037
Email: info@sapunano.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Sapu Nano Expands International Development of Sapu003 and Appoints Global Clinical Trials (GCT) as Lead CRO for Phase 1b Program
SINGAPORE, June 8, 2026 /PRNewswire/ -- arrivia and KrisFlyer, the lifestyle rewards programme of the Singapore Airlines Group, are elevating member benefits with the launch of cruise bookings using KrisFlyer miles. This enhanced partnership offers KrisFlyer members expanded opportunities to utilise miles through KrisFlyer Cruise, arrivia's exclusive cruise platform. This enhanced partnership enables members to unlock high-value cruise holidays through KrisFlyer Cruise, arrivia's dedicated cruise platform, giving members more meaningful ways to use their miles. Now, members can redeem KrisFlyer miles on an extensive selection of cruise itineraries offered by over 40 world-leading cruise lines.
With this latest enhancement, members can redeem KrisFlyer miles for a cruise or combine miles and cash to unlock greater flexibility and access higher-value travel experiences, across over 30,000 itineraries operated by renowned cruise lines, including Royal Caribbean International, Disney Cruise Line, Princess Cruises, and more. These sailings span destinations worldwide, including key growth regions such as Southeast Asia and Australia, reflecting rising demand for cruise travel.
KrisFlyer members can continue to earn 2 KrisFlyer miles for every USD 1 spent on cruise fares, creating an ecosystem where members can both earn and redeem within the same category, driving deeper engagement with the programme. John Williams, Chief Operating Officer (COO), arrivia International, said, "This partnership is about giving KrisFlyer members more meaningful ways to use their miles. Cruises represent one of the fastest-growing and highest-value travel categories, and by offering cruising as a redemption option to KrisFlyer members, we are enabling members to access more rewarding experiences while helping drive stronger engagement within the programme. With thousands of sailings globally and dedicated cruise specialists, we are making cruise more accessible than ever."
Easy Steps to Book a Cruise
- Visit https://krisflyercruise.com
- Log in with KrisFlyer membership details
- Browse and select from thousands of itineraries
- Book online or connect with cruise experts for personalized assistance
The launch comes at a pivotal time, as cruising continues its strong growth trajectory globally and across Asia Pacific. In 2025, the cruise industry reached a record 37.2 million passengers worldwide, marking a 7.5% year-on-year increase, with continued momentum expected in the years ahead. As demand for cruise travel rises and repeat intent remains strong, KrisFlyer members can now enjoy a more seamless travel journey that extends beyond air travel into end-to-end holiday experiences at sea.
Social Media & Website
Instagram: @KrisflyerCruise
KrisFlyer Cruise Website: https://krisflyercruise.com/
ABOUT KRISFLYER:
KrisFlyer is the lifestyle rewards programme of the Singapore Airlines Group, with over 11.8 million members worldwide. Members enjoy extensive earn and redemption opportunities across flights, shopping, dining and travel experiences through Singapore Airlines, Scoot, KrisShop, Kris+, Pelago and more than 1,700 global partner brands.
ABOUT ARRIVIA:
arrivia is a global leader in travel loyalty and rewards solutions, helping brands expand redemption ecosystems and drive deeper member engagement through high-value travel experiences and technology-enabled loyalty solutions.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Arrivia and KrisFlyer Expand Partnership to Launch Cruise Redemptions with Miles
